Top Markets
#1 DogBull DogBull +108.92%
#2 MarsCoin MarsCoin +75.44%
#3 Siacoin Siacoin +55.80%
#4 ADO Protocol ADO Protocol +52.90%
#5 The Bitcoin Bull The Bitcoin Bull +26.92%
#6 Ontology Gas Ontology Gas +22.45%
#7 Useless Coin Useless Coin +17.91%
#8 Apertum Apertum +14.84%
#9 Arowana Arowana +12.72%
#10 UnifAI Network UnifAI Network +11.97%
Coin of the day
DogBull DogBull
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Rang in Aktien #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Aktienkurs
$4.74
Zuletzt synchronisiert: 2026-08-31
Marktkapitalisierung
$372.19M
Veränderung (1 Tag)
-2.47%
Veränderung (1 Jahr)
-1.04%
Land
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategorie

Healthcare
P/S-Verhältnis für Lexeo Therapeutics, Inc. Common Stock (LXEO)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Lexeo Therapeutics, Inc. Common Stock beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Lexeo Therapeutics, Inc. Common Stock von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH